Summary
Global Markets Direct’s, ‘Typhoid Fever - Pipeline Review, H1 2016’, provides an overview of the Typhoid Fever pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Typhoid Fever
- The report reviews pipeline therapeutics for Typhoid Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Typhoid Fever therapeutics and enlists all their major and minor projects
- The report assesses Typhoid Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Typhoid Fever
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Typhoid Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
GlaxoSmithKline Plc
Nanotherapeutics, Inc.
Prokarium Limited
Protein Potential, LLC
Sanofi
Shantha Biotechnics Limited
SK Chemicals Co., Ltd.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Typhoid Fever Overview 7
Therapeutics Development 8
Pipeline Products for Typhoid Fever - Overview 8
Pipeline Products for Typhoid Fever - Comparative Analysis 9
Typhoid Fever - Therapeutics under Development by Companies 10
Typhoid Fever - Therapeutics under Investigation by Universities/Institutes 11
Typhoid Fever - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Typhoid Fever - Products under Development by Companies 16
Typhoid Fever - Products under Investigation by Universities/Institutes 17
Typhoid Fever - Companies Involved in Therapeutics Development 18
GlaxoSmithKline Plc 18
Nanotherapeutics, Inc. 19
Prokarium Limited 20
Protein Potential, LLC 21
Sanofi 22
Shantha Biotechnics Limited 23
SK Chemicals Co., Ltd. 24
Zydus Cadila Healthcare Limited 25
Typhoid Fever - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(paratyphoid + typhoid) vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(shigella + typhoid) vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(Streptococcal pneumonia + typhoid) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Typhella - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Typhetec - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
typhoid vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
typhoid vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
typhoid vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ViCRM-197 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Typhoid Fever - Recent Pipeline Updates 46
Typhoid Fever - Dormant Projects 47
Typhoid Fever - Discontinued Products 48
Typhoid Fever - Product Development Milestones 49
Featured News & Press Releases 49
Mar 11, 2013: Prokarium and University Of Birmingham Receive £0.4m Grant To Develop Next Generation Vaccines 49
Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine 49
Jun 23, 2011: Sanofi Pasteur’s Typhim VI Receives Prequalification from World Health Organization 49
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate 50
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine 50
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine 51
Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results in Phase II Clinical Study 51
Nov 29, 1994: Food and Drug Administration Grants License For A New Typhoid Fever Vaccine 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54
List of Tables
Number of Products under Development for Typhoid Fever, H1 2016 8
Number of Products under Development for Typhoid Fever - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Comparative Analysis by Unknown Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H1 2016 18
Typhoid Fever - Pipeline by Nanotherapeutics, Inc., H1 2016 19
Typhoid Fever - Pipeline by Prokarium Limited, H1 2016 20
Typhoid Fever - Pipeline by Protein Potential, LLC, H1 2016 21
Typhoid Fever - Pipeline by Sanofi, H1 2016 22
Typhoid Fever - Pipeline by Shantha Biotechnics Limited, H1 2016 23
Typhoid Fever - Pipeline by SK Chemicals Co., Ltd., H1 2016 24
Typhoid Fever - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Typhoid Fever Therapeutics - Recent Pipeline Updates, H1 2016 46
Typhoid Fever - Dormant Projects, H1 2016 47
Typhoid Fever - Discontinued Products, H1 2016 48
List of Figures
Number of Products under Development for Typhoid Fever, H1 2016 8
Number of Products under Development for Typhoid Fever - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32
